SLC16A1 and malignant colon neoplasm: The MCT1 inhibitor α-cyano-4-hydroxycinnamate sensitised colon cancer cells to cisplatin by a mechanism involving the down regulation of MDRI and MRP1 genes, which are involved in multidrug resistance (MDR) [122].